The hook effect is a well-recognized problem that can occur in assays of most tumour markers, including alpha feto-protein (AFP). We present a case of hepatoblastoma in a baby. The diagnosis was delayed as a result of unrecognized 'hooking' of a very high AFP concentration in the automated immunoassay method used. The falsely low result obtained was considered normal for the patient's age and supported the diagnosis of benign haemangioendothelioma. Liaison between clinical and laboratory staff was critical in obtaining an accurate AFP result, proceeding to liver biopsy and establishing the definitive diagnosis of hepatoblastoma. While the reasons and solutions for hook effect have been well researched and published, we believe the presence of extremely high serum AFP concentration in some hepatoblastoma patients means that the hook effect remains a problem and can generate erroneously low AFP results despite assay reformulation by manufacturers. Therefore constant vigilance by laboratory staff is still needed.
Introduction
Hepatoblastoma is a rare malignant liver tumour which occurs in childhood. Most cases present between the ages of six months and three years with an asymptomatic abdominal mass. There is a male predominance, and in the majority of cases the tumour arises in the right lobe of the liver. 1, 2 In contrast to neuroblastoma (the most common malignant abdominal tumour in this age group) and benign abdominal tumours (e.g. infantile hepatic haemangioendotheliomas) the vast majority of hepatoblastomas secrete large quantities of alpha-fetoprotein (AFP). 3 Measurement of serum AFP concentrations is therefore a useful adjunct to abdominal ultrasound scanning in the di¡erential diagnosis of abdominal tumours in children.
Early identi¢cation of hepatoblastoma is critical to patient survival. Asymptomatic benign hepatic haemangioendotheliomas typically involute and regress spontaneously and require very little medical intervention, whereas malignant hepatoblastomas require prompt aggressive treatment with chemotherapy and surgical resection. 1 We present a patient in whom the diagnosis of hepatoblastoma was delayed due to an extremely high concentration of AFP causing a high-dose hook e¡ect on an immunoassay platform. This patient was given a provi-sional diagnosis of hepatic haemangioendothelioma and the ¢nal diagnosis was only con¢rmed following identi¢cation of the immunoassay hook problem.
Case Report
A two-month old Caucasian baby girl presented to her general practitioner (GP) for a routine eight-week postnatal check. During examination, the GP noted a distended abdomen. No other abnormality was found; she was an alert and active baby with no dysmorphic features. She had been born at full term plus nine days by caesarean section due to failure to progress in labour. An episode of physiological jaundice in the neonatal period responded well to phototherapy and there were no other concerns during that period.
In view of her distended abdomen, she was referred to her local hospital on the 26th of April 2005, and on physical examination the medical team found a large abdominal mass. The liver was enlarged; there was no splenomegaly; there were no cardiovascular or chest problems and she had normal movements and re£exes. A diagnosis of neuroblastoma was considered. The di¡erential diagnosis of neuroblastoma includes other tumours of early childhood, such as rabdomyosarcoma, lymphoma, hepatic haemangioendothelioma and hepatoblastoma.
Ultrasound examination of the abdomen showed that the abdominal aorta and inferior vena cava were compressed by a large anterior mass medial to the portal vein. This mass appeared to arise from the left lobe of the liver with a generous vascular supply from the coeliac axis. Within the liver a vascular, non-calci¢ed lesion measuring 9 Â7 Â8 cm was seen. Kidneys, adrenal glands and spleen were normal. The patient also underwent a computed tomography (CT) scan, which con¢rmed the presence of an intrinsic vascular mass within the left lobe of the liver.
Initial investigations showed that she was slightly anaemic with haemoglobin 10.6 g/dL. Bilirubin, gamma-glutamyl transferase, aspartate transaminase and alkaline phosphatase were all within age-related reference ranges. Urine homovanillic acid (HVA) and vanillylmandelic acid (VMA) were not elevated. On the basis of normal urine HVA and hydroxymethoxymandelic acid (HMMA) and the vascular appearance of the tumour, a neuroblastoma was considered unlikely and a provisional diagnosis of hepatic haemangioendothelioma was made. At this time the patient was well and feeding satisfactorily. She was therefore discharged home on prednisolone 2 mg/kg/day. Regular reviews were planned, with serial ultrasound scans to monitor the expected regression of her abdominal mass. On 27th of April, a serum sample was taken for AFP measurement at the local hospital. The result was very high, but it was not laboratory policy to phone such results to the requesting clinicians, who in this case failed to follow up the written report.
Over the next two weeks, the patient's clinical condition deteriorated. She developed feeding di⁄culties and increasing abdominal distension. On the 21st of May, she was referred to the paediatric liver unit at St. James's Hospital in Leeds. Magnetic resonance imaging (MRI) was performed and tumour size was measured as 15 Â14.6 Â10 cm. Tumour appearance was noted to be compatible with, but not classical of, haemangioendothelioma and in view of this serum was sent to the Leeds laboratory for AFP measurement. The result was reported as 452 kU/L (Bayer, Advia Centaur), and this was not considered to be signi¢cantly elevated (age related reference range 0--217 kU/L). 4 At that time the Leeds clinicians also obtained the AFP result on the sample taken one month earlier at the local hospital, which was reported as 1,844,000 kU/L (Roche E170, Roche Diagnostics, UK). This was clearly at variance with the result reported using the Bayer Centaur. Following discussion between the clinical team and the laboratory, a further sample was obtained for AFP measurement. Due to the small size of the initial sample, it was not possible to repeat the AFP measurement following dilution. A second sample gave an AFP result of 525 kU/L on direct measurement. However, when this sample was diluted 10,000-fold prior to analysis (100-fold manual dilution followed by 100-fold automated dilution on board the analyzer), this gave a result of 2,461,400 kU/L (Bayer Centaur). This con¢rmed that the previous result of 452 kU/L was erroneously low due to a high-dose hook e¡ect a¡ecting the AFP method on the Bayer Centaur. On the basis of the con¢rmed grossly elevated AFP result, a liver biopsy was performed on the 31st of May, which con¢rmed a hepatoblastoma of predominantly foetal type histologically. The tumour stage was IIIP according to PRETEXT (pre-treatment extent of disease) criteria. 5 The patient received adjuvant preoperative chemotherapy at her local hospital to reduce tumour size and improve delineation of the tumour margin to facilitate complete resection. The half-life of AFP in the circulation is 4--9 days; a fall in AFP concentration during chemotherapy indicates tumour responsiveness. 6 AFP concentrations have gradually decreased, indicating a good response to the chemotherapeutic regimen, and it is hoped that this patient's tumour will be fully resectable at the end of her treatment course.
Discussion
Hepatoblastoma accounts for approximately 1% of all childhood malignancies. The mainstay of treatment is complete surgical resection of the tumour following a course of adjuvant preoperative chemotherapy to render the tumour more solid, less prone to bleeding and better delineated from healthy liver parenchyma. 2 Five-year survival ¢gures are currently 75%; patients with unresectable disease either due to tumour volume, involvement of both liver lobes or metastatic lung disease have a poor prognosis and are most likely to die from the disease. 7 It is therefore crucial that the diagnosis is made early in the course of the disease.
Bleeding and infection can occur as complications in 5--10% of patients undergoing liver biopsy. Diagnostic biopsies are therefore not performed unless there is a strong suspicion that the tumour is malignant. 2 Although not speci¢c for hepatoblastoma, an elevated serum AFP concentration in a patient with an asymptomatic abdominal mass is strongly suggestive of a malignant tumour. Measurement of serum AFP is therefore useful in selecting patients for biopsy, and appropriate age-related reference ranges must be used to aid the interpretation of serum AFP results. Serum AFP concentrations are elevated above the adult reference range in all healthy infants up to eight months of age (mean serum AFP concentrations at birth in term infants 40,177 kU/L, falling to adult concentrations of o10 kU/L by eight months of age). 4 Consequently, AFP results of several hundred kU/L would not be considered unusual in a two-or three-month-old patient.
High-dose hook e¡ects in immunoassays have been recognized for many years. Sandwich-type immuno-assays where the analyte, the solid phase antibody and the liquid-phase-labelled antibody react simultaneously (one-step immunometric assays) are particularly susceptible to the hook e¡ect. 8 The phenomenon is most likely to occur in assay systems for analytes such as AFP, prostate-speci¢c antigen (PSA), human chorionic gonadotrophin (hCG), ferritin and thyroglobulin, where the range of possible analyte concentration spans several orders of magnitude. High-dose hook occurs when the number of analyte molecules exceeds the number of antibody binding sites --this point is called the'hook threshold'.When the analyte concentration exceeds the hook threshold, there is competition between free analyte and analyte bound to the liquid-phase-labelled antibody for a limited number of binding sites on the solid-phase antibody. Therefore, as the analyte concentration increases there is a paradoxical decrease in the amount of liquid-phase-labelled antibody sandwiched to the solid phase. This results in a falsely low apparent analyte concentration. 9 Hook e¡ects can be averted by increasing the antibody: analyte ratio either by assay reformulation or by dilution of the sample. Many modern sandwich assays have been formulated to minimize the potential for hook e¡ect. This has led to a general belief that highdose e¡ect has been circumvented and is no longer considered a problem in these assays.
Despite the fact that the Roche E170 and the Bayer Centaur AFP assays are both one-step sandwich immunoassays, the hook e¡ect was only observed on the Bayer Advia Centaur. The most common approaches developed to minimize the possibility of hook e¡ect are to increase the concentration and the binding capacity of solid phase capture antibody. 8 It is therefore expected that di¡erent AFP methods will have di¡erent thresholds for hook e¡ect.
Kit manufacturers quote a 'non-hook upper limit'. This is the highest concentration at which they have tested for, and shown the absence of, a hook e¡ect. The true hook threshold for an assay largely depends on the concentration and binding capacity of the antibodies used in that assay, and may be at a much higher concentration than the non-hook upper limit, as seen for the Roche E170.
The Roche method employs a biotinylated mouse monoclonal AFP-speci¢c antibody and a mouse monoclonal AFP-speci¢c antibody labelled with a ruthenium complex, with chemiluminescent detection; the non-hook upper limit of the assay is quoted as 1,000,000 kU/L (manufacturer's data). The Bayer Centaur method employs a mouse monoclonal anti-AFP antibody coupled to paramagnetic particles and a rabbit polyclonal anti-AFP antibody labelled with an acridinium ester, with chemiluminescent detection; the non-hook upper limit of the assay is quoted as 830,000 kU/L (manufacturer's data).
The tumour markers assay manufacturers have succeeded in shifting the threshold of the hook e¡ect to a higher AFP concentration, yet the problem has not been completely eliminated. Patients with hepatoblastoma often have extremely high serum AFP concentrations --up to 100,000--1,000,000 times the normal value for age 10 --serum AFP concentrations that fall above the hook threshold for many assays.
The AFPassay in our laboratory is performed in accordance with the manufacturer's speci¢cations and satis-¢es all the quality requirements for assay validation. NACB Guidelines on Quality Requirements for the use of Tumour Markers 11 recommend that laboratories have de¢ned protocols for identifying specimens that have 'hooked' . One approach would be to perform the AFP measurement on both neat and diluted serum. This, however, is impractical and has signi¢cant cost implications. An alternative approach requires accurate clinical information and good communication between clinician and the laboratory so that samples with potentially high tumour marker concentrations can be identi¢ed and diluted. Clinical scientists need to play a proactive role in encouraging clinicians to provide them with clinical information. Participation of clinical scientists in multi disciplinary team meetings and ward rounds where cases like this can be discussed creates the opportunity to communicate the limitations of laboratory methods.
This case illustrates that all laboratories providing tumour marker assays, particularly measurement of AFP in paediatric samples, should be alert to the continuing possibility of hook e¡ects. Manual dilution of these samples is recommended in order to ensure that the reported result is accurate, and that cases of hepatoblastoma are not missed. 11 This case also reinforces the critical importance of exchange of information between clinician and laboratory.
